[HTML][HTML] Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving …
Y Song, Y Peng, C Qin, Y Wang, W Yang… - … for Immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background Immune checkpoint blockade (ICB) therapy holds promise in metastatic
urothelial carcinoma (UC). Fibroblast growth factor receptor 3 (FGFR3) mutation drives T-cell …
urothelial carcinoma (UC). Fibroblast growth factor receptor 3 (FGFR3) mutation drives T-cell …
Final Results from SAUL, a Single-arm International Study of Atezolizumab in Unselected Patients with Pretreated Locally Advanced/Metastatic Urinary Tract …
Background and objective We assessed the safety of atezolizumab in unselected patients
(including understudied populations typically excluded from clinical trials) with pretreated …
(including understudied populations typically excluded from clinical trials) with pretreated …
[PDF][PDF] RADIOLABELLED PD-L1 INHIBITOR MONOCLONAL ANTIBODIES: SYNTHESIS, CHARACTERIZATION AND VALIDATION
MACR FORTUNATO - 2023 - run.unl.pt
Monoclonal antibodies have great potential for the treatment of cancer through
Immunotherapy. However, certain immunotherapies, like PD-L1 inhibitors, are dependent of …
Immunotherapy. However, certain immunotherapies, like PD-L1 inhibitors, are dependent of …